Julianna Lisziewicz

American Gene Technologies Appoints Dr. Marcus A. Conant as Special Advisor to the CEO

Retrieved on: 
Friday, October 1, 2021
AGT, Food, Infection, Clinical trial, Cancer, HIV/AIDS, Criticism of the Food and Drug Administration, Orphan, Diagnosis, Maryland Department of Natural Resources, Person, FDA, Patient, Optimism, Population, Physician, Degenerative disease, Immune system, University of California, San Francisco, UNAIDS, University, San Francisco AIDS Foundation, Pain, PKU, Julianna Lisziewicz, Disease, Empathy, Technology, ClinicalTrials.gov, Research, Lead, Cell, Maryland Department of Health, Quality of life, HIV, Inherited disorders of trafficking, AIDS, Education, GLOBE, Pharmaceutical industry, Vaccine

ROCKVILLE, Md., Oct. 01, 2021 (GLOBE NEWSWIRE) -- American Gene Technologies (AGT) announces the appointment of Dr. Marcus A. Conant, a leading dermatologist in the U.S. and one of the first physicians to diagnose and treat AIDS, as special advisor to AGT CEO Jeff Galvin.

Key Points: 
  • ROCKVILLE, Md., Oct. 01, 2021 (GLOBE NEWSWIRE) -- American Gene Technologies (AGT) announces the appointment of Dr. Marcus A. Conant, a leading dermatologist in the U.S. and one of the first physicians to diagnose and treat AIDS, as special advisor to AGT CEO Jeff Galvin.
  • Im elated and honored to have Marcus on board as an advisor, said AGT CEO Jeff Galvin.
  • Dr. Conant was the first physician to diagnose HIV in San Francisco while running the inpatient dermatology service at the University of California San Francisco.
  • Dr. Conant conducted early clinical trials, persevering despite seeing 94% of patients die during the epidemics first years.

NexImmune to Announce Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

Retrieved on: 
Tuesday, July 27, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Immunotherapy, Virotherapy, Medical specialties, Immune system, Julianna Lisziewicz

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the bodys own T cells to generate a specific, potent, and durable immune response.

Key Points: 
  • NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the bodys own T cells to generate a specific, potent, and durable immune response.
  • The backbone of NexImmunes approach is a proprietary Artificial Immune Modulation (AIM) nanoparticle technology platform.
  • The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response.
  • Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements.

Treos Bio Announces the Appointment of Ruti Alon to its Board of Directors

Retrieved on: 
Tuesday, June 1, 2021
Biomarkers, Biotechnology, Chemical pathology, The Receiving End of Sirens, Palm Treo, Biology, Medicine, Life sciences, Julianna Lisziewicz

LONDON, June 01, 2021 (GLOBE NEWSWIRE) -- Treos Bio Limited (Treos), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the appointment of Ruti Alon to its Board of Directors.

Key Points: 
  • LONDON, June 01, 2021 (GLOBE NEWSWIRE) -- Treos Bio Limited (Treos), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the appointment of Ruti Alon to its Board of Directors.
  • Ms. Alon joins Treos with over 40 years of executive and entrepreneurial expertise as a life sciences investor, mentor and leader for private and public biotechnology companies.
  • I am excited to join Treos Bio, a company dedicated to transforming the cancer immunotherapy treatment paradigm, commented Ms. Alon.
  • Treos Bio uses computational data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide-based cancer immunotherapies.

Treos Bio Announces $14 Million Convertible Loan Note Financing to Advance Platform of Computationally Designed Peptide-Based Cancer Immunotherapies

Retrieved on: 
Wednesday, March 31, 2021
Branches of biology, Biology, Clinical medicine, Biomarkers, Cancer immunotherapy, Cell biology, Immunotherapy, Virotherapy, Julianna Lisziewicz

The financing was led by Luminous Ventures and the UK Governments Future Fund, both first-time investors in Treos.

Key Points: 
  • The financing was led by Luminous Ventures and the UK Governments Future Fund, both first-time investors in Treos.
  • Treos Bio uses computational data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies.
  • This technology aims to address the challenge of the variability of individual patients clinical responses to cancer immunotherapies.
  • Treos launched in February 2017 and has raised $28 million Series A funding led by shareholders of BXR Group.

Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis’ Proprietary POCare Technologies for the Generation and Expansion of T-Cells

Retrieved on: 
Tuesday, July 14, 2020
Health, Medicine, Clinical medicine, Cancer treatments, Virotherapy, Drug discovery, Immunotherapy, Clinical trial, Julianna Lisziewicz

Under the agreement, the parties plan to conduct one or more collaborative cell-based research projects aligned with local medical centers.

Key Points: 
  • Under the agreement, the parties plan to conduct one or more collaborative cell-based research projects aligned with local medical centers.
  • The agreement is part of the Orgenesis strategy of growing and expanding the POCare Network, which includes leading hospitals and research institutes around the world.
  • The first collaboration under the agreement will focus on the clinical development of CAR-T and whole cell-based vaccine platform for use in cancer immunotherapies.
  • Dr Miomir Kneevi, CEO of Educell, commented, We are excited to team with Orgenesis to potentially advance these breakthrough therapies into clinical trials using cutting edge technologies.

Immunomic Therapeutics to Present at AACR Virtual Annual Meeting II

Retrieved on: 
Thursday, June 11, 2020
Research, Infectious diseases, Clinical trials, Stem cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Medicine, Medical specialties, Clinical medicine, Immunology, Cancer immunotherapy, Immunotherapy, Cytokine, Vaccine, Active immunotherapy, Julianna Lisziewicz, UNITE, Immunomic Therapeutics, Inc.

In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory.

Key Points: 
  • In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory.
  • This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases.
  • UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy.
  • For more information, please visit www.immunomix.com .

Global Cancer Immunotherapy Market Report 2020: Market Accounted for 50% o the Overall Oncology Drugs Market, Generating $75 Billion in 2019 and $115 Billion by 2023

Retrieved on: 
Wednesday, December 4, 2019
Medicine, Clinical medicine, Medical specialties, Cancer treatments, Cancer immunotherapy, Immunotherapy, Oncology, Cancer vaccine, Cancer, Active immunotherapy, Julianna Lisziewicz

Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $75 billion in 2019 alone and are forecast to surpass $115 billion in 2023.

Key Points: 
  • Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $75 billion in 2019 alone and are forecast to surpass $115 billion in 2023.
  • Immunotherapy is forecast to become the oncology treatment of choice by 2026 with an estimated 60% of previously treated cancer patients likely to adopt immunotherapy in this timeframe.
  • Cancer immunotherapy also expands into multiple indications and our analysis indicates that key immunotherapies including anti-PD-1 drugs, dendritic cell vaccines, T-cell therapies, and cancer vaccines are all driving the market.
  • To that end, the cancer immunotherapy market is forecast to hit $115 billion by 2023.

Treos Bio Presents Positive Data on Its Off-the-Shelf Shared Antigen-Based Cancer Vaccine Against Microsatellite-stable metastatic colorectal cancer and Personalized Vaccines Against Three Metastatic cancers

Retrieved on: 
Thursday, November 7, 2019
Vaccination, Medicine, Medical specialties, Cancer vaccine, Health, Vaccine, Breast cancer, Tumor antigen vaccine, Julianna Lisziewicz

PAScal enabled the development of two families of effective shared antigen-based cancer vaccines (off-the-shelf and personalized) that target 19 cancer indications and are commercially scalable, without need for tumor biopsy and on-demand manufacturing.

Key Points: 
  • PAScal enabled the development of two families of effective shared antigen-based cancer vaccines (off-the-shelf and personalized) that target 19 cancer indications and are commercially scalable, without need for tumor biopsy and on-demand manufacturing.
  • Treos Bio uses a knowledgebase and algorithm embedded in its proprietary PASCal tool to develop cancer vaccines.
  • Personalized vaccines administered to three HLA-genotyped metastatic cancer patients (with ovarian-, breast- and colorectal cancer) induced CD8+ T-cell responses against an average of 12 different vaccine antigens, from the 12-13 vaccine peptides administered for each patient.
  • Treos is the first in the immunotherapy field to generate positive data for classically cold tumors: MSS mCRC, ovarian cancer and breast cancer, said Christopher C. Gallen, MD, PhD, and Chairman of Treos Bio.

BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs

Retrieved on: 
Wednesday, September 4, 2019
Biotechnology, AIDS, Health, Pharmaceutical, Research, Infectious diseases, Science, Clinical trials, Medical specialties, Medicine, Health, Prevention of HIV/AIDS, Hepatotoxins, Management of HIV/AIDS, Vaccine, HIV/AIDS, Immunotherapy, Tuberculosis, Division of Acquired Immunodeficiency Syndrome, Julianna Lisziewicz

This partnership includes an initial equity investment of $55 million, which is expected to close within the next week.

Key Points: 
  • This partnership includes an initial equity investment of $55 million, which is expected to close within the next week.
  • The funds will be used to develop preclinical vaccine and immunotherapy candidates to prevent HIV and tuberculosis infection as well as to lead to durable antiretroviral therapy-free remission of HIV disease.
  • BioNTechs innovative mRNA-based approach and in-depth understanding of the immune system offer exciting pathways to develop effective new immune-based therapies that could dramatically reduce the global incidence of HIV and tuberculosis.
  • Under the terms of the agreement, the collaboration will fund the identification of potential HIV and tuberculosis vaccine and immunotherapy candidates and their pre-clinical development.

ImaginAb Announces Collaboration on CD8 Imaging Agent with Roche

Retrieved on: 
Tuesday, July 9, 2019
Medicine, Medical specialties, Clinical medicine, Immune system, Cancer treatments, Immunology, Cancer immunotherapy, Immunotherapy, Oncology, T cell, Julianna Lisziewicz

LOS ANGELES, July 9, 2019 /PRNewswire/ --ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced today that it has entered into a non-exclusive license and collaboration agreement with Roche.

Key Points: 
  • LOS ANGELES, July 9, 2019 /PRNewswire/ --ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced today that it has entered into a non-exclusive license and collaboration agreement with Roche.
  • Under the terms of the agreement, Roche will use ImaginAb's novel minibody CD8 T cell imaging agent in immuno-oncology clinical trials for multiple types of cancers.
  • ImaginAb's CD8 T cell imaging agent is designed to be used with PET scan technology to non-invasively determine changes in CD8 T cell tumor infiltrates induced by immunotherapy treatments.
  • Ian Wilson, Chief Executive Officer of ImaginAb, said:"We are thrilled about our collaboration with Roche, a leading pharmaceutical company focused on cancer treatment and diagnostics.